Morningstar

Vertex Pharmaceuticals On Track for Largest Percent Increase Since January — Data Talk

Provided by Dow Jones

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $405.74, up $14.10 or 3.6% 




     --Would be highest close since Aug. 4, 2025, when it closed at $472.27 



     --On pace for largest percent increase since Jan. 31, 2025, when it rose 5.31% 



     --Currently up four of the past five days 



     --Up 0.75% year-to-date; on pace for best year since 2023, when it rose 40.9% 



     --Down 21.48% from its all-time closing high of $516.74 on Nov. 8, 2024 



     --Down 12.20% from 52 weeks ago (Oct. 2, 2024), when it closed at $462.14 



     --Down 21.48% from its 52-week closing high of $516.74 on Nov. 8, 2024 



     --Up 10.69% from its 52-week closing low of $366.54 on Aug. 8, 2025 



     --Traded as high as $407.50; highest intraday level since Aug. 5, 2025, when it hit $414.88 



     --Up 4.05% at today's intraday high; largest intraday percent increase since Aug. 6, 2025, when it rose as much as 4.15% 





     All data as of 3:01:03 PM ET 





     Source: Dow Jones Market Data, FactSet 





  (END) Dow Jones Newswires



  October 01, 2025 15:20 ET (19:20 GMT)


Copyright (c) 2025 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
 
With a 3.3% dividend yield and earnings growth expected to exceed management’s outlook, this 4-star stock stands out in a struggling sector. 
 
 
Andrew Bischof, CFA, CPA 
 
 
 
The Thrilling 37
 
Just a few strict screens can narrow the field to an elite group of funds. 
 
 
Russel Kinnel 
 
 
 
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
 
Ask the Analyst columnist Amy Arnott answers a grab bag of reader questions about bond ETFs, TIPS, retirement planning, and more. 
 
 
Amy C. Arnott, CFA and Ivanna Hampton 
 
 
 
3 Stocks to Invest In With More Room to Run
 
These stocks are up significantly in 2026, yet still look undervalued today. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center